FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 13, 2017 -- Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 13, 2017 Category: Drugs & Pharmacology Source Type: news
Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
SEOUL (Reuters) - A unit of healthcare conglomerate Johnson& Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch
Patients with RA who switched from infliximab to the biosimilar SB2 had ACR20 responses, adverse events, and immunogenicity profiles at 78 weeks similar to those in patients who continued infliximab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Long-term Studies Back Biologic-to-Biosimilar Switch Long-term Studies Back Biologic-to-Biosimilar Switch
Researchers in Europe compared clinical response, remission, and immunogenicity to determine whether switching between innovator infliximab and the CTP-13 biosimilar has any effect on outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
IBD patients may stay healthier when doctors monitor medications before they lose efficacy
(Beth Israel Deaconess Medical Center) Proactive monitoring of blood levels of the therapeutic drug infliximab was associated with improved outcomes including lower risk of surgery and hospitalization. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 3, 2017 Category: International Medicine & Public Health Source Type: news
Pfizer Files Suit Over Remicade Contracts Pfizer Files Suit Over Remicade Contracts
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Surgery an Alternative to Infliximab for Some People With Crohn ’ s Disease Surgery an Alternative to Infliximab for Some People With Crohn ’ s Disease
Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 21, 2017 Category: Surgery Tags: General Surgery News Source Type: news
Pfizer files lawsuit against J & J ’s exclusionary contracts for Remicade
Pfizer has filed a lawsuit against Johnson& Johnson (J&J) in the US District Court for the Eastern District of Pennsylvania to ensure patients and providers have access to major, lower-cost biosimilar therapies. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news
Pfizer sues J&J, claims ‘anticompetitive practices’ over Remicade biosimilar
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 20, 2017 Category: Pharmaceuticals Source Type: news
Merck, Samsung Bioepis launch discounted U.S. Remicade alternative
NEW YORK/SEOUL (Reuters) - Merck& Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson& Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Merck launches biosimilar version of J & J blockbuster Remicade
Merck and Co. Inc. on Monday became the second pharmaceutical company to launch a biosimilar version of Remicade, a drug that generates billions of dollars a year in sales for Johnson& Johnson.
Renflexis, the Merck biosimilar product, was approved by the Food and Drug Administration on April 21 as a treatment for rheumatoid arthritis, Crohn's disease, ulcerative colitis and ankylosing spondylitis.
It is the first medicine available in the United States under a global biosimilars develop ment and… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 24, 2017 Category: Health Management Authors: John George Source Type: news
Samsung Bioepis launches U.S. sales of Remicade biosmiliar
SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said it started U.S sales of its copy of Johnson& Johnson's rheumatoid arthritis drug Remicade on Monday - a move set to further undermine sales of the U.S. firm's top-selling drug. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Nonmedical Biosimilar Switch Results Surprise Investigators Nonmedical Biosimilar Switch Results Surprise Investigators
When the Danish government mandated a switch to the infliximab biosimilar, researchers had the perfect opportunity to study the effect on patients with rheumatologic inflammatory disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD Pregnancy and the Pharmacokinetics of Anti-TNF Agents in IBD
This study found that infliximab and adalimumab present differing effects.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Infliximab Induction Levels Predict IBD Treatment Failure Infliximab Induction Levels Predict IBD Treatment Failure
Lower infliximab trough levels during induction are associated with an increased risk of treatment failure during maintenance in patients with inflammatory bowel disease (IBD), researchers report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 8, 2017 Category: Surgery Tags: Gastroenterology News Source Type: news
